You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 24, 2025

CLINICAL TRIALS PROFILE FOR NULYTELY-FLAVORED


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Nulytely-flavored

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00164151 ↗ A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy. Completed Braintree Laboratories Phase 3 2001-06-01 The objective of this study is to determine the efficacy and safety of HalfLytely as compared to Visicol as bowel preparations before colonoscopic examination.
NCT00164164 ↗ HalfLytely Bowel Prep System for Colonoscopy Completed Braintree Laboratories Phase 3 1999-08-01 The purpose of the this study was to compare the safety and efficacy of HalfLytely (2L NULYTELY + 20mg bisacodyl) to NULYTELY for preparation prior to colonoscopy.
NCT00425594 ↗ A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population Completed Braintree Laboratories Phase 4 2007-01-01 This randomized, parallel, multi-center, single-blind study is designed to compare the safety and efficacy of 3 bowel preparations in pediatric subjects scheduled to undergo a colonoscopy for a routinely accepted indication.
NCT00689026 ↗ Efficacy of Lubiprostone in Combination With Standard PEG Preparation Terminated Takeda Pharmaceuticals North America, Inc. N/A 2008-05-01 A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics.
NCT00689026 ↗ Efficacy of Lubiprostone in Combination With Standard PEG Preparation Terminated Augusta University N/A 2008-05-01 A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nulytely-flavored

Condition Name

Condition Name for Nulytely-flavored
Intervention Trials
Colonoscopy 4
Preparation for Colonoscopy 2
Bowel Preparation for Colonoscopy 1
Diabetes Mellitus, Type 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nulytely-flavored
Intervention Trials
Diabetes Mellitus 1
Diabetes Mellitus, Type 2 1
Diabetes Mellitus, Type 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nulytely-flavored

Trials by Country

Trials by Country for Nulytely-flavored
Location Trials
United States 30
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nulytely-flavored
Location Trials
Texas 3
Illinois 3
Massachusetts 2
Minnesota 2
Indiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nulytely-flavored

Clinical Trial Phase

Clinical Trial Phase for Nulytely-flavored
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nulytely-flavored
Clinical Trial Phase Trials
Completed 8
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nulytely-flavored

Sponsor Name

Sponsor Name for Nulytely-flavored
Sponsor Trials
Braintree Laboratories 3
Gastroenterology Services, Ltd. 2
Takeda Pharmaceuticals North America, Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nulytely-flavored
Sponsor Trials
Industry 6
Other 5
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

NuLYTELY Flavored: Clinical Trials, Market Analysis, and Projections

Introduction

NuLYTELY Flavored is a widely used bowel preparation solution, primarily indicated for the cleansing of the colon in preparation for colonoscopy and other gastrointestinal procedures. This article will delve into the clinical trials, market analysis, and future projections for NuLYTELY Flavored.

Clinical Trials and Efficacy

Overview of Clinical Trials

Clinical trials for NuLYTELY Flavored have been extensive and have demonstrated its efficacy in colon cleansing. These trials have included adult and pediatric populations, showing that the solution effectively cleanses the bowel, usually within four hours, in over 95% of patients[4].

Safety and Efficacy Data

The safety and efficacy of NuLYTELY Flavored are supported by adequate and well-controlled clinical trials. In pediatric patients aged 6 months and older, the solution has been shown to be safe and effective, although careful monitoring is recommended for possible hypoglycemia and electrolyte imbalances[2][4].

Adverse Reactions

Common adverse reactions include nausea, abdominal fullness, bloating, abdominal cramps, vomiting, and anal irritation. These reactions are generally transient and subside rapidly. Rare but serious adverse reactions such as seizures, associated with electrolyte abnormalities, and allergic reactions have also been reported[2][4].

Market Analysis

Current Market Position

NuLYTELY Flavored is a leading product in the bowel preparation market, known for its effectiveness and relatively good tolerability compared to other preparations. The availability of various flavors (Cherry, Lemon-Lime, Orange, and Pineapple) enhances patient compliance by improving the taste[4].

Competitors and Alternatives

The market for bowel preparation solutions is competitive, with other products like sodium phosphate (NaP) preparations and sulfate-free PEG formulations. However, NuLYTELY Flavored remains a preferred choice due to its balanced electrolyte composition and minimal impact on fluid and electrolyte balance[2].

Patient Preferences

Patients often prefer flavored preparations and smaller-volume regimens to improve tolerability. NuLYTELY Flavored addresses these preferences by offering a palatable solution that can be administered in a split-dose regimen, which may improve preparation efficacy and patient convenience[2].

Market Projections

Growth Trends

The demand for bowel preparation solutions is expected to grow due to the increasing prevalence of gastrointestinal diseases and the rising number of colonoscopies performed. NuLYTELY Flavored is likely to benefit from this trend, given its established reputation and continuous improvements in formulation and administration methods[2].

Technological Advancements

Future advancements in bowel preparation solutions may include more convenient packaging, improved flavors, and potentially reduced volumes. NuLYTELY Flavored is well-positioned to adapt to these advancements, maintaining its market share through innovation and patient-centric design[2].

Regulatory Environment

Regulatory approvals and guidelines play a crucial role in the market for bowel preparation solutions. NuLYTELY Flavored has a strong regulatory profile, with clear guidelines for its use and contraindications. Adherence to these regulations will be essential for maintaining market position[4].

Use in Specific Populations

Pediatric Use

NuLYTELY Flavored is safe and effective in pediatric patients aged 6 months and older. However, careful monitoring is necessary, especially for possible hypoglycemia and electrolyte imbalances. Dehydration and hypokalemia have been reported in some pediatric cases[2][4].

Geriatric Use

While clinical studies did not include sufficient numbers of subjects aged 65 and over, other reported clinical experience has not identified significant differences in responses between the elderly and younger patients. However, caution is advised due to the potential for serious adverse events in older adults[2][4].

Pregnancy and Nursing Mothers

NuLYTELY Flavored should be used in pregnant women only if clearly needed, as animal reproduction studies have not been conducted. Similarly, caution is advised when administering the solution to nursing mothers due to the lack of data on its excretion in human milk[2][4].

Administration and Preparation

Dosage and Administration

NuLYTELY Flavored must be reconstituted with water before use and should not be mixed with other liquids or starch-based thickeners. The solution is typically administered orally at a rate of 240 mL every 10 minutes for adults, and 25 mL/kg/hour for pediatric patients[2][4].

Storage and Handling

The reconstituted solution should be refrigerated and used within 48 hours. It is more palatable when chilled, but this is not recommended for infants[4].

Key Takeaways

  • Efficacy: NuLYTELY Flavored is highly effective in colon cleansing, suitable for both adult and pediatric populations.
  • Safety: Common adverse reactions are transient, but serious reactions such as seizures and allergic reactions can occur.
  • Market Position: A leading product in the bowel preparation market, known for its balanced electrolyte composition and good tolerability.
  • Future Projections: Expected to benefit from growing demand for bowel preparation solutions and advancements in formulation and administration.
  • Regulatory Compliance: Strong regulatory profile with clear guidelines for use and contraindications.

FAQs

Q: What is the primary indication for NuLYTELY Flavored?

A: The primary indication for NuLYTELY Flavored is the cleansing of the colon in preparation for colonoscopy and other gastrointestinal procedures.

Q: How is NuLYTELY Flavored administered?

A: NuLYTELY Flavored is administered orally after reconstitution with water. The typical dosage is 240 mL every 10 minutes for adults and 25 mL/kg/hour for pediatric patients.

Q: What are the common adverse reactions to NuLYTELY Flavored?

A: Common adverse reactions include nausea, abdominal fullness, bloating, abdominal cramps, vomiting, and anal irritation.

Q: Can NuLYTELY Flavored be used in pediatric patients?

A: Yes, NuLYTELY Flavored is safe and effective in pediatric patients aged 6 months and older, but careful monitoring is necessary.

Q: Are there any contraindications for using NuLYTELY Flavored?

A: Yes, NuLYTELY Flavored is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or toxic megacolon, and in those known to be hypersensitive to any of its components[4].

Sources

  1. NuLYTELY: Package Insert / Prescribing Information - Drugs.com
  2. Colonoscopy preparation - ASGE
  3. Drug Trials Snapshots: NULIBRY - FDA (Note: This source is not directly related to NuLYTELY but was included in the search results)
  4. NuLYTELY® with Flavor Packs PEG-3350, Sodium Chloride ... - DailyMed
  5. NULYTELY WITH FLAVOR PACKS- polyethylene glycol 3350 ... - DailyMed

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.